← Leaderboards
Bin Zhang
Northwestern University
$12,434,815
Attributed
$16,726,716
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,726,716 · 8
By mechanism
R01$16,726,716 · 8
Top collaborators
- Deyu Fang5 shared
- Yong Wan5 shared
- Chad A. Mirkin4 shared
- Weiguo Cui2 shared
Most similar at Northwestern University
Same institution · by research overlap
- Chad A. Mirkin$20,335,625
- Maciej S Lesniak$30,155,882
- John A Kessler$26,477,132
- Timothy L Sita$223,924
- Max Wang$198,604
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorTumor MicroenvironmentNeoplastic CellTumor ImmunityMediatingCellsImmunotherapyMalignant NeoplasmsSignal TransductionT-LymphocyteMolecularCd8-Positive T-LymphocytesImmuneIn VitroCancer ImmunotherapyImmunosuppressionCancer PatientTumor EscapeTumor PromotionInsightCd8b1 GeneTumor GrowthRegulatory T-LymphocyteCancer Therapy
Grant awards (41)
Sustaining antitumor effector CD8+ T cells for cancer therapy$652,206
R01 · FY2025 · CA · contact PI
Targeting posttranslational modifications of CD73 in TNBCs$644,746
R01 · FY2025 · CA
A deubiquitination module controls Treg adaptation to tumor microenvironment$560,370
R01 · FY2025 · CA
Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids$513,840
R01 · FY2025 · CA
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells$202,022
R01 · FY2025 · CA · contact PI
Sustaining antitumor effector CD8+ T cells for cancer therapy$633,355
R01 · FY2024 · CA · contact PI
A deubiquitination module controls Treg adaptation to tumor microenvironment$533,802
R01 · FY2024 · CA
Targeting posttranslational modifications of CD73 in TNBCs$533,393
R01 · FY2024 · CA
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells$512,222
R01 · FY2024 · CA · contact PI
Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids$490,839
R01 · FY2024 · CA
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells$560,248
R01 · FY2023 · CA · contact PI
A deubiquitination module controls Treg adaptation to tumor microenvironment$552,115
R01 · FY2023 · CA
Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids$508,916
R01 · FY2023 · CA
WEE1 inhibition and tumor immunity$252,247
R01 · FY2023 · CA · contact PI
Targeting posttranslational modifications of CD73 in TNBCs$1
R01 · FY2023 · CA
Targeting posttranslational modifications of CD73 in TNBCs$663,953
R01 · FY2022 · CA
A deubiquitination module controls Treg adaptation to tumor microenvironment$553,526
R01 · FY2022 · CA
Innovative Research for Cancer Nanotechnology (IRCN) for Enhancing Melanoma-specific Immune Responses by the Rational Design of Spherical Nucleic Acids$521,890
R01 · FY2022 · CA
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells$521,582
R01 · FY2022 · CA · contact PI
WEE1 inhibition and tumor immunity$411,600
R01 · FY2022 · CA · contact PI
Targeting posttranslational modifications of CD73 in TNBCs$659,221
R01 · FY2021 · CA
A deubiquitination module controls Treg adaptation to tumor microenvironment$561,629
R01 · FY2021 · CA
WEE1 inhibition and tumor immunity$420,000
R01 · FY2021 · CA · contact PI
The role of GPSM3 in tumor-promoting emergency myelopoiesis$361,425
R01 · FY2021 · CA · contact PI
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells$221,903
R01 · FY2021 · CA · contact PI
The distinct role of cysteinyl leukotriene receptor for myeloid-derived suppressive cells$495,420
R01 · FY2020 · CA · contact PI
The role of GPSM3 in tumor-promoting emergency myelopoiesis$361,425
R01 · FY2020 · CA · contact PI
WEE1 inhibition and tumor immunity$213,256
R01 · FY2020 · CA · contact PI
WEE1 inhibition and tumor immunity$436,922
R01 · FY2019 · CA · contact PI
The role of GPSM3 in tumor-promoting emergency myelopoiesis$350,581
R01 · FY2019 · CA · contact PI
WEE1 inhibition and tumor immunity$446,500
R01 · FY2018 · CA · contact PI
The role of GPSM3 in tumor-promoting emergency myelopoiesis$361,425
R01 · FY2018 · CA · contact PI
The role of GPSM3 in tumor-promoting emergency myelopoiesis$359,710
R01 · FY2017 · CA · contact PI
CD73 and tumor immunity$311,894
R01 · FY2015 · CA · contact PI
CD73 and tumor immunity$302,537
R01 · FY2014 · CA · contact PI
CD73 and tumor immunity$58,509
R01 · FY2014 · CA · contact PI
CD73 and tumor immunity$293,181
R01 · FY2013 · CA · contact PI
CD73 and Tumor Immunity-CD73 and CTLA-4 combination Blockade in Ovarian Cancer$55,294
R01 · FY2013 · CA · contact PI
CD73 and tumor immunity$170,853
R01 · FY2012 · CA · contact PI
CD73 and tumor immunity$142,372
R01 · FY2012 · CA · contact PI
CD73 and tumor immunity$319,786
R01 · FY2011 · CA · contact PI